SAMSUNG BIOLOGICS CO.,LTD.
Financials
Valuation Metrics
SAMSUNG BIOLOGICS CO.,LTD.'s Market Cap is ₩59.0T. At end of 2025 it was ₩78.5T. Ranked #8 of 2,419 in KR market (top 0.3%), #8 of 781 on KOSPI (top 1%), #1 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.4%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 58.97T KRW | KR#8/2,419 Sec#1/231 |
| Revenue | 4.55T KRW | KR#141/2,419 Sec#2/231 |
| Net Income | 1.98T KRW | KR#27/2,419 Sec#1/231 |
| Total Assets | 12.65T KRW | KR#100/2,419 Sec#2/231 |
| Net Assets | 8.36T KRW | KR#68/2,419 Sec#2/231 |
| Employees | 5,011 | KR#59/2,419 Sec#1/231 |
| Value | ||
| P/E | 29.72x | KR#1,292/2,419 Sec#80/231 |
| P/B | 7.05x | KR#2,293/2,419 Sec#200/231 |
| PEG | 0.55x | KR#704/2,419 Sec#45/231 |
| P/S | 12.97x | KR#2,291/2,419 Sec#167/231 |
| EV/EBITDA | 26.39x | KR#1,131/2,419 Sec#69/231 |
| FCF Yield | 1.45% | KR#1,090/2,419 Sec#75/231 |
| Profitability | ||
| ROE | 23.73% | KR#116/2,419 Sec#10/231 |
| ROA | 15.68% | KR#106/2,419 Sec#9/231 |
| Op. Margin | 50.02% | KR#11/2,419 Sec#2/231 |
| Revenue Growth | -9.64% | KR#1,918/2,419 Sec#178/231 |
| Earnings Growth | 54.31% | KR#535/2,419 Sec#36/231 |
| Financial Health | ||
| Debt Ratio | 51.31% | KR#979/2,419 Sec#114/231 |
| Total Debt | 1.33T KRW | KR#169/2,419 Sec#4/231 |
| FCF | 856.07B KRW | KR#40/2,419 Sec#1/231 |
| Cash | 288.58B KRW | KR#206/2,419 Sec#4/231 |
| Current Ratio | 1.80x | KR#980/2,419 Sec#108/231 |
| Net Debt/EBITDA | 0.46x | KR#664/2,419 Sec#40/231 |
| Performance | ||
| 1Y Return | -14.21% | KR#1,194/2,419 Sec#81/231 |
| 1M Return | -13.10% | KR#2,226/2,419 Sec#210/231 |
| From 52W High | -35.88% | KR#821/2,419 Sec#55/231 |
| 1Y MDD | -36.74% | KR#464/2,419 Sec#33/231 |
| Trading | ||
| Volume | 57,400 shares | KR#1,087/2,419 Sec#127/231 |
| Trading Value | 73.62B KRW | KR#51/2,419 Sec#2/231 |
| Foreign Own. | 13.14% | KR#369/2,419 Sec#25/231 |
| Per Share | ||
| EPS | 42,866 KRW | KR#20/2,419 Sec#1/231 |
| BPS | 180,638 KRW | KR#79/2,419 Sec#3/231 |
Company Info
Established in 2011, this company is a biopharmaceutical CDMO specialist that incorporated development and commercialization divisions by acquiring 100% of Samsung Bioepis shares in 2022. It operates production facilities in Songdo, Incheon, offering contract manufacturing and cell line/process development services, and currently sells 10 types of biosimilars globally. The company is expanding from antibody drug-focused CDMO to next-generation biopharmaceuticals, aiming to complete an End-to-End service system with the launch of an organoid business in 2025. Samsung Biologics is headquartered in Yeonsu-gu, Incheon.